Your shopping cart is empty

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Onyx’s Kyprolis to Compete With Velcade After Winning Accelerated Approval for Multiple Myeloma

Drug Industry Daily

July 23, 2012 | Vol. 11 No. 143

Onyx’s Kyprolis to Compete With Velcade After Winning Accelerated Approval for Multiple Myeloma

Onyx Pharmaceuticals’ Kyprolis just bagged accelerated approval for multiple myeloma patients who have received at least two prior therapies.

This article is viewable by subscribers only. To view this article, please select an option below.

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.